Drug Safety

Graph AI raises $3 mn from Bessemer to target $8 bn drug safety market

California-based Graph AI raised $3 million in seed funding led by Bessemer Venture Partners to scale its AI-driven pharmacovigilance platform for global drug safety and compliance

Updated On: 16 Oct 2025 | 3:01 PM IST

Cough syrup-linked deaths in MP rise to 22 as two more children succumb

These children from Chhindwara died due to suspected kidney failure, which is linked to the consumption of 'toxic' Coldrif cough syrup

Updated On: 09 Oct 2025 | 11:21 AM IST

Cough syrup deaths: PIL in SC seeks CBI probe, nationwide safety review

A PIL has been filed in the Supreme Court seeking inquiry and systemic reform in drug safety mechanisms in the wake of deaths of children in Madhya Pradesh and Rajasthan allegedly due to consumption of toxic cough syrups. The PIL, filed by advocate Vishal Tiwari, seeks a court-monitored probe into the incidents and urges the constitution of a National Judicial Commission or Expert Committee headed by a retired Supreme Court judge. The PIL requests that all pending FIRs and investigations concerning the deaths of children caused by toxic cough syrups across states be transferred to the CBI. It seeks a probe under the supervision of a retired Supreme Court judge to ensure fairness and uniformity. The petition contends that separate state-level investigations have led to fragmented accountability, enabling repeated lapses that allow hazardous formulations to reach the market. The petition comes amid reports from Madhya Pradesh and Rajasthan, where several children allegedly died afte

Updated On: 07 Oct 2025 | 1:15 PM IST

India's heart aches: Cardiac medication sales surge 50% in 5 years

India sees a 50 per cent surge in cardiac drug sales between 2021 and 2025, reflecting a worrying rise in heart disease cases and early diagnoses. Experts call for urgent preventive strategies

Updated On: 22 Jul 2025 | 6:35 PM IST

111 drug samples tested in November found 'not of standard quality': CDSCO

Central Drugs Standard Control Organisation (CDSCO) has found 41 drug samples tested in the central drug laboratories in November as 'not of standard quality' (NSQ), official sources said. Besides, 70 drug samples tested by the state drugs testing laboratories have also been identified as NSQ in November, they said. Identification of drug samples as NSQ is done based on failure of the drug sample in one or the other specified quality parameters. "The failure is specific to the drug products of the batch tested by the government laboratory and it does not warrant any concerns on the other drug products available in the market," an official said. Two drug samples were identified as spurious drugs in November. Out of the two samples, one was picked by Bihar Drugs Control Authority and the other by CDSCO, Ghaziabad, the sources said. The drugs were made by unauthorised and unknown manufacturers, using brand names of other companies. Action to identify NSQ and spurious medicines is ta

Updated On: 28 Dec 2024 | 12:30 PM IST

USFDA restricts imports of certain Viatris drugs made at India facility

The FDA has issued a warning letter to Viatris related to its drug manufacturing facility in Indore in the central Indian state of Madhya Pradesh

Updated On: 23 Dec 2024 | 11:06 PM IST

New rules ease testing for drug imports from US, EU, Australia, and Japan

Under new guidelines, testing will be reduced to one sample every two years or one sample from 20 consecutive consignments, whichever comes first

Updated On: 25 Sep 2024 | 9:50 AM IST

Eli Lilly's popular drug Mounjaro stuck at Indian regulators' counter

Eli Lilly's Mounjaro, a blockbuster diabetes medication and a highly popular obesity treatment is still awaiting approval from CDSCO despite a SEC clearance

Updated On: 04 Jul 2024 | 12:09 PM IST

Health ministry plans drug licensing changes to ensure drug safety

Proposals aim to standardise drug manufacturing practices after a few Indian medicines were flagged as 'substandard' by the WHO

Updated On: 15 Sep 2023 | 10:47 AM IST

DGCI asks labs to priortise mandatory testing of cough syrup before exports

With India making testing of cough syrups before export mandatory from June 1, the Drugs Controller General of India (DCGI) has asked specified state laboratories to examine such samples from manufacturers on "top priority and issue the test report at the earliest". Cough syrup exporters will have to produce a certificate of analysis issued by a government laboratory before the product is exported, effective June 1, the Directorate General of Foreign Trade (DGFT) said in a notification on Monday. The move came amid instances of quality concerns being raised abroad on cough syrups exported by Indian firms. "The export of cough syrup shall be permitted to be exported subject to export samples being tested and production of a certificate of analysis issued by any of the laboratories..., with effect from June 1, 2023," the notification stated. On Wednesday, the country's top drug regulator, DCGI, wrote to state drug controllers of Gujarat, Karnataka, Kerala, Madhya Pradesh, Maharashtr

Updated On: 25 May 2023 | 11:12 AM IST

Letters: Drug safety assurance

Apropos Bhupesh Bhandari's article, "Listen to Dinesh Thakur" (May 6), it is correct that the Indian pharmaceutical sector makes the finest medicines in the world

Updated On: 08 May 2016 | 9:56 PM IST